Merck & Co. has stopped a trio of phase 3 blood cancer trials after one study suggested the benefits of the BTK inhibitor may fail to outweigh the risks, bringing the curtain down on a program stemming from a $2.7 billion takeover.
The phase 3 Bellwave program was testing Merck’s BTK inhibitor, nemtabrutinib, in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Merck stopped one of the trials, Bellwave-011, after the external data monitoring committee’s review suggested the risks may outweigh the benefits in the study.
After confirming the external experts’ conclusions, Merck discontinued the broader clinical development program, including the phase 3 trials Bellwave-008 and Bellwave-010. The phase 3 studies were testing nemtabrutinib as a monotherapy and in combination in various populations of CLL and SLL patients.
The termination torpedoes the pursuit of blockbuster markets that Merck embarked on when it agreed to buy ArQule for $2.7 billion in 2019. Back then, nemtabrutinib, also called ARQ 531 and MK-1026, was flying high after triggering durable responses in patients with B-cell malignancies in an early-phase trial. At least six companies mulled striking a deal with ArQule in 2018 and 2019.
Merck paid a more than 100% premium to land its target. The takeover put Merck in a race with Eli Lilly, which bought a rival BTK inhibitor in its $8 billion takeover of Loxo Oncology. Lilly won FDA approval for its BTK inhibitor, Jaypirca, in 2023 and expanded into CLL and SLL in 2025.
Hopes for nemtabrutinib began fading years before Merck called time on the program. When it bought ArQule, Merck valued the acquired R&D project at $2.3 billion. The drugmaker knocked $275 million off that figure in 2021 in response to changes in expected development costs and a delay to the anticipated launch.
Merck recorded a $1.7 billion nemtabrutinib charge in 2022 after talks with regulatory agencies revealed that development would take longer than expected. Following the changes, the company placed a $418 million valuation on the project, which it retained through its latest annual report.